Gottsegen National Cardiovascular Center — Clinical Trial Site

34 Registered trials

10 Currently recruiting

Organisation

Gottsegen National Cardiovascular Center

Location

Budapest, Hungary

Identifier

ORG-100043314

Address

Kerulet, Haller Utca 29/IX., IX. Kerulet, 1096, Hungary

Departments

-
#1301: Felnőtt Szívsebészeti Osztály
#2604:Felnott Kardiologiai Osztály
Adult Cardiac Surgery
Adult cardiology department
Cardiology
Cardiology Department
Department of Adult Cardiology
Felnőtt kardiológiai osztály
Gyermekszív Központ
HU10001: Gyermekszív Központ
Intenziv Terapias Reszleg
Kardiológia
Klinikai Farmakologiai Osztaly
N/A
Pediatric Heart Center

Clinical trials at this site (34)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults… Recruiting

2024-519830-22-00 Heart failure due to systemic left ventricular systolic 5 2026-04-27
A study to learn more about how well finerenone works, how safe it is, and how it moves into, through, and out of the body compared to place… Recruiting

2024-519829-38-00 Heart failure due to systemic left ventricular systolic 5 2026-01-09
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
Open-label, single-arm, non-controlled trial to evaluate the safety and tolerability of treprostinil sodium in children below the age of 18 … Recruiting

2023-505082-91-00 Pulmonary Arterial Hypertension (PAH) 5 2024-05-29
Randomized trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy in… Recruiting

2023-504351-26-01 Pulmonary arterial hypertension (group I) 11 2023-12-06
A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericigua… Recruiting

2022-501238-52-00 Heart failure due to systemic left ventricular systolic 10 2023-03-23
A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent … Recruiting

2023-506791-27-00 pulmonary arterial hypertension 5 2022-04-22
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A clinical study of sotatercept in people with pulmonary arterial hypertension Ended

2024-518687-12-00 Pulmonary Arterial Hypertension (PAH) 4 2025-06-19
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
Parent and/or Legal Guardian ICF and Adult patient ICF: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study wi… Ended

2022-501012-34-00 Pulmonary Arterial Hypertension 5 2020-02-27
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertens… Ended

2023-509305-68-00 Pulmonary arterial hypertension (PAH) 5 2019-05-16
A clinical study to confirm the doses of selexipag to be used in children with pulmonary arterial hypertension Ended

2022-503042-42-00 Pulmonary Arterial Hypertension 4 2018-07-23
A study to evaluate the safety and effectiveness of a new gene therapy (XC001) for people with coronary artery disease and reduced heart fun… Ended

2025-521325-33-00 Chronic angina and left ventricular dysfunction due to 4 2026-03-18
A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended

2024-512278-92-00 Pulmonary Arterial Hypertension (PAH) 4 2024-12-09